Tracking the UTHR option chain helps you see every strike and expiry on United Therapeutics Corp in one view, so you can quickly identify the contracts that fit your thesis and your risk. United Therapeutics Corp's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of UTHR options activity at a glance. Use our scanner to monitor the UTHR option chain in real time and filter for the UTHR options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For UTHR stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the UTHR option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where UTHR stock options are being actively traded and where they are not.
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin analogue treprostinil to enhance the exercise ability in PAH patients and pulmonary hypertension associated with interstitial lung disease (PH-ILD); Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Unituxin, a monoclonal antibody for treating high-risk neuroblastoma; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
The company also engages in developing Tyvaso DPI, a dry powder inhalation form of Tyvaso; Remunity Pump, a small, lightweight, durable pump and separate controller; RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Tyvaso PERFECT and TETON studies, which are the studies of Tyvaso in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls United Therapeutics Corp's full chain across every expiry, highlights the most liquid strikes, and lets you screen UTHR options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of UTHR stock options — let the full option chain come to you, pre-filtered and ready to trade.
